Top stories of 2022 for cancer cell and gene therapy.
2022 has been a year filled with triumphs for the field of cancer cell and gene therapy. Breakthroughs in research, survivor milestones, FDA approvals and more have defined a great year for this emerging field of cancer treatment.
ACGT scientist Brian Brown, PhD, making progress with macrophage therapy.
Brian Brown, PhD, an ACGT Research Fellow, is making progress in his ACGT-funded development of a CAR T-cell therapy to target a particular immune cell called macrophages. In tests on mice subjects, Dr. Brown’s new therapy shrank tumors by killing macrophages and causing a positive immune response.
As the end of 2022 approaches, everyone at Alliance for Cancer Gene Therapy wishes you and your family a happy holidays. These last few weeks are a final opportunity to make an impact in the fight against cancer by supporting cell and gene therapy science.
The latest from around the cancer cell and gene therapy research world.
Barbara Lavery, Chief Program Officer of ACGT, will be participating in the 9th-annual Immuno-Oncology 360° Summit taking place February 7-10, 2023, at the New York Marriott at the Brooklyn Bridge in Brooklyn. The IO360 Summit offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting immuno-oncology.
Plenary topics include Cell Therapy, Biomarkers, Assay Development, Discovery, Preclinical, Imaging Advancements, Clinical Operations, Business Developments, Translational Science, RNA Therapeutics, and Clinical Developments.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.